ICCM — IceCure Medical Ltd

IceCure Medical Ltd (ICCM) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Sales: Approximately $1.3 million, marking a record quarter.
• Full Year 2025 Revenue: Total revenue reached $3.4 million, also a record for the company.

2. Strategic Updates and Business Highlights

• FDA Clearance: ProSense received FDA marketing authorization for treating low-risk early-stage breast cancer, significantly boosting sales and interest.
• ASBRS Recommendation: The American Society of Breast Surgeons recommended cryoablation as a treatment option, enhancing ProSense's credibility and potential market adoption.
• Customer Pipeline: Strong growth in signed contracts and installations, with notable installations at major hospitals, including a large university hospital.
• International Expansion: Submitted a Class III application to Health Canada to expand ProSense's indications to patients aged 60 and above, targeting approximately 7,130 new cases annually.
• Post-Marketing Study: Plans to initiate a post-marketing study with 30 sites, expected to accelerate national rollout and increase adoption.

3. Forward Guidance and Outlook

• Sales Growth: Anticipates continued sales growth in 2026, with plans to triple the U.S. commercial team to meet rising demand.
• Reimbursement Strategy: Actively pursuing reimbursement coverage beyond Medicare, with CPT1 code expected to enhance reimbursement rates by early 2028.
• Market Position: The company believes it will maintain a competitive edge due to the unique FDA clearance of ProSense, with no immediate competition expected in the U.S. market.

4. Bad News, Challenges, or Points of Concern

• Regulatory Risks: While FDA clearance is a significant achievement, the company faces risks associated with regulatory approvals in other markets, including Canada and Japan.
• Reimbursement Uncertainty: Although reimbursement is established, the transition to CPT1 and securing broader coverage remains a challenge that could impact adoption rates.
• Sales Cycle: The sales cycle for ProSense installations can take several months to nine months, which may delay revenue recognition.

5. Notable Q&A Insights

• Reimbursement Coverage: Plans to approach Medicare Advantage and private payers for broader coverage were discussed, indicating a proactive strategy to enhance reimbursement.
• Post-Marketing Study Sites: High interest from identified sites for the post-marketing study, with expectations of rapid onboarding, although formal agreements are still in progress.
• International Opportunities: The potential for market expansion in Canada and Japan was highlighted, with specific numbers indicating significant new patient cases available for treatment.

Overall, IceCure Medical Ltd is positioned for growth following its FDA clearance and strategic recommendations from medical societies, although it must navigate regulatory and reimbursement challenges to fully capitalize on its market potential.